MedTrace Logo

Effect of Silymarin Against Methotrexate-induced Liver Injury in Rheumatic Diseases

NCT06277635 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 72

Last updated 2024-02-26

No results posted yet for this study

Summary

To study the effect of silymarin against methotrexate-induced liver injury in rheumatic diseases including rheumatoid arthritis, psoriatric arthritis and psoriasis

Conditions

Interventions

DRUG

Silymarin

Silymarin is randomly assigned to the participants for 12 weeks during study.

DRUG

Placebo

Placebo is randomly assigned to the participants for 12 weeks during study.

Sponsors & Collaborators

  • Phramongkutklao College of Medicine and Hospital

    lead OTHER

Principal Investigators

  • Rattapol Pakchotanon, M.D. · Phramongkutklao College of Medicine and Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
20 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-02-01
Primary Completion
2025-04-30
Completion
2025-04-30

Countries

  • Thailand

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06277635 on ClinicalTrials.gov